Data for Nanoformulated bisdemethoxycurcumin does not ameliorate pathology or cognitive impairment in 5xFAD transgenic mice

Antibody therapies are very costly and their limited accessibility and efficacy underscore the significant continuing importance of small molecule therapeutics. Curcuminoids are of great interest in neurodegenerative diseases, in particular in Alzheimer’s disease (AD).

Curcumin is the major curcuminoid in turmeric, the naturally occurring source of curcuminoids. However, comparatively little work has been conducted on structurally related molecules, including demethoxycurcumin and bisdemethoxycurcumin (BDMC). Building on prior observations showing beneficial effects of curcumin formulated in heavy-chain-ferritin nanoparticles (HFn-Cur) in vivo and in vitro, we examined whether these effects extend to nanoformulated BDMC (HFn-BDMC). 5xFAD transgenic mice were treated twice weekly, from 6.5 months to 8.5 months of age.